Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection
- 1 November 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500204
Abstract
PURPOSE: Gastric cancer (GC) is a significant global health challenge, often diagnosed late, limiting treatment success. Early detection through biomarkers is critical for better outcomes. This study developed a noninvasive, cost-effective tool using circulating cell-free DNA (cfDNA) sequencing and advanced modeling for early GC detection. METHODS: We performed low-coverage whole-genome sequencing on plasma from 404 patients with GC and 428 non-GC participants (healthy donors and patients with colorectal, esophageal, or liver cancer). Participants were divided into a training set (579) and a validation set (253). A deep learning model, GastricAI, was trained on raw cfDNA reads using Mamba, an advanced sequence model enhancing the structured state space model (S4) with adaptive parameters. Performance was evaluated in a second validation set (73 GC patients, 94 controls). RESULTS: In the first validation set, GastricAI achieved an area under receiver operating characteristic curve (AUROC) of 0.886 (95% CI, 0.842 to 0.930), accuracy of 0.846, sensitivity of 0.789, and specificity of 0.900. Across TNM stages, it recorded sensitivity/specificity of 0.920/0.738 (stage I), 0.846/0.900 (stage II), 0.811/0.900 (stage III), and 1.000/0.623 (stage IV). In the second validation set, it showed an AUROC of 0.850 (95% CI, 0.793 to 0.907), accuracy of 0.772, sensitivity of 0.973, and specificity of 0.617. GastricAI consistently detected intestinal, diffuse, and mixed GC subtypes per Lauren's classification and outperformed conventional biomarkers carbohydrate antigen 724 ( P < .001) and carcinoembryonic antigen ( P = .037). CONCLUSION: GastricAI provides a promising noninvasive method for GC detection via cfDNA sequencing, with high sensitivity and reasonable specificity. It holds potential for early screening to improve prognosis, although further prospective studies are needed to validate and refine its clinical utility across diverse populations.Keywords
This publication has 37 references indexed in Scilit:
- Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinomaCancer Cell, 2025
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation setAnnals of Oncology, 2021
- Novel potential tumor biomarkers: Circular RNAs and exosomal circular RNAs in gastrointestinal malignanciesJournal of Clinical Laboratory Analysis, 2020
- Burden of Gastric CancerClinical Gastroenterology and Hepatology, 2019
- GSA: Genome Sequence ArchiveGenomics, Proteomics & Bioinformatics, 2017
- Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-OriginCell, 2016
- Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosisBreast Cancer Research and Treatment, 2014
- Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer AssociationGastric Cancer, 2013
- Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the NetherlandsEuropean Journal of Cancer, 2010
- Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancerCancer Letters, 2008